Portal de Periódicos da CAPES

Antiviral mechanisms of two broad-spectrum monoclonal antibodies for rabies prophylaxis and therapy

2023; Frontiers Media; Volume: 14; Linguagem: Inglês

10.3389/fimmu.2023.1186063

1664-3224

Maira Zorzan, Martina Castellan, Matteo Gasparotto, Guilherme Dias de Melo, Barbara Zecchin, Stefania Leopardi, Alex Chen, Antonio Rosato, Alessandro Angelini, Hervé Bourhy, Davide Corti, Laura Cendron, Paola De Benedictis,

Poxvirus research and outbreaks

Rabies is an acute and lethal encephalomyelitis caused by lyssaviruses, among which rabies virus (RABV) is the most prevalent and important for public health. Although preventable through the post-exposure administration of rabies vaccine and immunoglobulins (RIGs), the disease is almost invariably fatal since the onset of clinical signs. Two human neutralizing monoclonal antibodies (mAbs), RVC20 and RVC58, have been shown to be effective in treating symptomatic rabies. To better understand how these mAbs work, we conducted structural modeling and